F. Peyron, R. Mc-leod, D. Ajzenberg, D. Contopoulos-ioannidis, F. Kieffer et al., Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches, PLoS Negl. Trop. Dis, vol.11, 2017.

C. Rudin, H. H. Hirsch, R. Spaelti, S. Schaedelin, and T. Klimkait, Decline of Seroprevalence and Incidence of Congenital Toxoplasmosis Despite Changing Prevention Policy-Three Decades of Cord-blood Screening in North-western Switzerland, Pediatr. Infect. Dis. J, vol.37, pp.1087-1092, 2018.

W. Kluver and . Grading-guide, , 2018.

F. Peyron, M. Wallon, F. Kieffer, J. Garweg, and . Toxoplasmosis, Infectious Diseases of the Fetus and Newborn Infant

J. S. Remington and J. O. Klein, , pp.949-1042, 2016.

E. K. Shwab, X. Zhu, D. Majumdar, H. F. Pena, S. M. Gennari et al., Geographical patterns of Toxoplasma gondii genetic diversity revealed by multilocus PCR-RFLP genotyping, Parasitology, vol.141, pp.453-461, 2014.

F. P. Vieira, M. D. Alves, L. M. Martins, A. L. Rangel, J. P. Dubey et al., Waterborne toxoplasmosis investigated and analysed under hydrogeological assessment: New data and perspectives for further research, Mem. Inst. Oswaldo Cruz, vol.110, pp.929-935, 2015.

M. Tourdjman, C. Tchéandjieu, H. De-valk, V. Goulet, and Y. Le-strat, Toxoplasmose chez les femmes enceintes en France: Évolution de la séroprévalence et des facteurs associés entre 1995 et 2010, à partir des Enquêtes nationales périnatales. English translation: Toxoplasmosis among pregnant women in France: Trends in seroprevalence and associated factors between, Bull. Epidemiol. Hebd, vol.15, pp.264-272, 1995.

M. Rabilloud, M. Wallon, and F. Peyron, In utero and at birth diagnosis of congenital toxoplasmosis: Use of likelihood ratios for clinical management, Pediatr. Infect. Dis. J, vol.29, pp.421-425, 2010.

M. Wallon and F. Peyron, Effect of Antenatal Treatment on the Severity of Congenital Toxoplasmosis, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol.62, pp.811-812, 2016.

J. E. Gaston and L. Vogl, Psychometric properties of the general well-being index, Qual. Life Res, vol.14, pp.71-75, 2005.

F. Peyron, J. G. Garweg, M. Wallon, E. Descloux, M. Rolland et al., Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance, Pediatr. Infect. Dis. J, vol.30, pp.597-600, 2011.

J. Gresset, H. Boisjoly, T. Q. Nguyen, J. Boutin, and M. Charest, Validation of French-language versions of the Visual Functioning Index (VF-14) and the Cataract Symptom Score, Can. J. Ophthalmol, vol.32, pp.31-37, 1997.

S. Rougier, J. G. Montoya, and F. Peyron, Lifelong Persistence of Toxoplasma Cysts: A Questionable Dogma? Trends Parasitol, vol.33, pp.93-101, 2017.

D. Grande, C. Galli, L. Schiavi, E. Dell'osso, L. Bruschi et al., Is Toxoplasma gondii a Trigger of Bipolar Disorder? Pathogens, vol.6, 2017.

E. Tedford,

, Glenn McConkey Neurophysiological Changes Induced by Chronic Toxoplasma gondii Infection, vol.6, 2017.

A. Prusa, D. C. Kasper, A. Pollak, A. Gleiss, T. Waldhoer et al., The Austrian Toxoplasmosis Register, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol.60, pp.4-10, 1992.

H. Autorité-de-santé, , 2017.

J. G. Montoya and J. S. Remington, Management of Toxoplasma gondii infection during pregnancy, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol.47, pp.554-566, 2008.

I. R. Dunay, K. Gajurel, R. Dhakal, O. Liesenfeld, and J. G. Montoya, Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice, Clin. Microbiol. Rev, 2018.

F. Peyron, M. Wallon, C. Liou, and P. Garner, Treatments for toxoplasmosis in pregnancy, Cochrane Database Syst. Rev, p.18, 2000.

F. Rahman, P. Birowo, I. S. Widyahening, and N. Rasyid, Effect of citrus-based products on urine profile: A systematic review and meta-analysis, vol.6, 2017.

R. Owusu, K. P. Asante, E. Mahama, E. Awini, T. Anyorigiya et al., Glucose-6-Phosphate Dehydrogenase Deficiency and Haemoglobin Drop after Sulphadoxine-Pyrimethamine Use for Intermittent Preventive Treatment of Malaria during Pregnancy in Ghana-A Cohort Study, PLoS ONE, vol.10, 2015.

A. Hotop, H. Hlobil, and U. Gross, Efficacy of rapid treatment initiation following primary Toxoplasma gondii infection during pregnancy, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol.54, pp.1545-1552, 2012.

L. Mandelbrot, F. Kieffer, R. Sitta, H. Laurichesse-delmas, N. Winer et al., Prenatal therapy with pyrimethamine + sulfadiazine versus spiramycin to reduce placental transmission of toxoplasmosis: A multicenter, randomized trial, Am. J. Obstet. Gynecol

M. Wallon, F. Peyron, C. Cornu, S. Vinault, M. Abrahamowicz et al., Congenital toxoplasma infection: Monthly prenatal screening decreases transmission rate and improves clinical outcome at age 3 years, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol.56, pp.1223-1231, 2013.

R. Thiébaut, S. Leproust, G. Chêne, and R. Gilbert, Effectiveness of prenatal treatment for congenital toxoplasmosis: A meta-analysis of individual patients' data, Lancet Lond. Engl, vol.369, pp.115-122, 2007.

M. Wallon, L. Kodjikian, C. Binquet, J. Garweg, J. Fleury et al., Long-term ocular prognosis in 327 children with congenital toxoplasmosis, Pediatrics, vol.113, pp.1567-1572, 2004.

M. Wallon and F. Peyron, Congenital Toxoplasmosis: A Plea for a Neglected Disease

M. Cortina-borja, H. K. Tan, M. Wallon, M. Paul, A. Prusa et al., Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: An observational prospective cohort study, PLoS Med, 2010.

F. Kieffer, M. Wallon, P. Garcia, P. Thulliez, F. Peyron et al., Risk factors for retinochoroiditis during the first 2 years of life in infants with treated congenital toxoplasmosis, Pediatr. Infect. Dis. J, vol.27, pp.27-32, 2008.

P. Hohlfeld, F. Daffos, J. M. Costa, P. Thulliez, F. Forestier et al., Prenatal diagnosis of congenital toxoplasmosis with a polymerase-chain-reaction test on amniotic fluid, N. Engl. J. Med, vol.331, pp.695-699, 1994.

L. Delhaes, H. Yera, S. Ache, and V. Tsatsaris, Houfflin-Debarge, V. Contribution of molecular diagnosis to congenital toxoplasmosis, Diagn. Microbiol. Infect. Dis, vol.76, pp.244-247, 2013.

V. Malan, L. Bussières, N. Winer, J. Jais, A. Baptiste et al., Effect of Cell-Free DNA Screening vs Direct Invasive Diagnosis on Miscarriage Rates in Women With Pregnancies at High Risk of Trisomy 21: A Randomized Clinical Trial, JAMA, vol.320, 2018.

L. H. Bosch-driessen, F. D. Verbraak, M. S. Suttorp-schulten, R. L. Van-ruyven, A. M. Klok et al., A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis, Am. J. Ophthalmol, vol.134, pp.34-40, 2002.

J. G. Montoya, Systematic screening and treatment of toxoplasmosis during pregnancy: Is the glass half full or half empty?, Am. J. Obstet. Gynecol, vol.219, pp.315-319, 2018.

F. Dhombres, S. Friszer, P. Maurice, M. Gonzales, F. Kieffer et al., Prognosis of Fetal Parenchymal Cerebral Lesions without Ventriculomegaly in Congenital Toxoplasmosis Infection, Fetal Diagn. Ther, vol.41, pp.8-14, 2017.

M. Wallon, F. Kieffer, C. Huissoud, and F. Peyron, Cesarean delivery or induction of labor does not prevent vertical transmission of toxoplasmosis in late pregnancy, Int. J. Gynecol. Obstet, vol.129, pp.176-177, 2015.

M. Lebech, D. H. Joynson, H. M. Seitz, P. Thulliez, R. E. Gilbert et al., Classification system and case definitions of Toxoplasma gondii infection in immunocompetent pregnant women and their congenitally infected offspring. European Research Network on Congenital Toxoplasmosis, Eur. J. Clin. Microbiol. Infect. Dis. Off. Publ. Eur. Soc. Clin. Microbiol, vol.15, pp.799-805, 1996.

I. Jaisson-hot, M. Wallon, M. Kurdi, P. Thulliez, S. Kahi et al.,

P. P. Méd and . Fr, , vol.30, pp.1001-1004, 1983.

R. Mcleod, K. Boyer, T. Karrison, K. Kasza, C. Swisher et al., Outcome of treatment for congenital toxoplasmosis, 1981-2004: The National Collaborative Chicago-Based, Congenital Toxoplasmosis Study, Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am, vol.42, pp.1383-1394, 2006.

J. Teil, D. Dupont, B. Charpiat, S. Corvaisier, T. Vial et al., Treatment of Congenital Toxoplasmosis: Safety of the Sulfadoxine-Pyrimethamine Combination in Children Based on a Method of Causality Assessment, Pediatr. Infect. Dis. J, vol.35, pp.634-638, 2016.

R. R. Ben-harari, E. Goodwin, and J. Casoy, Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review, Drugs RD, vol.17, pp.523-544, 2017.

E. Chapey, M. Wallon, G. Debize, M. Rabilloud, and F. Peyron, Diagnosis of congenital toxoplasmosis by using a whole-blood gamma interferon release assay, J. Clin. Microbiol, vol.48, pp.41-45, 2010.

M. Wallon, G. Cozon, R. Ecochard, P. Lewin, and F. Peyron, Serological rebound in congenital toxoplasmosis: Long-term follow-up of 133 children, Eur. J. Pediatr, vol.160, pp.534-540, 2001.

L. Beraud, M. Rabilloud, J. Fleury, M. Wallon, and F. Peyron,

, J. Fr. Ophtalmol, vol.36, pp.494-498, 2013.

M. Wallon, J. G. Garweg, M. Abrahamowicz, C. Cornu, S. Vinault et al., Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence, Pediatrics, vol.133, pp.601-608, 2014.

J. G. Garweg, J. Scherrer, M. Wallon, L. Kodjikian, and F. Peyron, Reactivation of ocular toxoplasmosis during pregnancy, BJOG Int. J. Obstet. Gynaecol, vol.112, pp.241-242, 2005.

Y. Zhang, X. Lin, and F. Lu, Current treatment of ocular toxoplasmosis in immunocompetent patients: A network meta-analysis, Acta Trop, vol.185, pp.52-62, 2018.